BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal

Reuters12-01

** Shares of women's health firm Daré Bioscience DARE.O rise 6% to $1.91 premarket

** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm

** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co

** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations

** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation

** Including session's move, stock down ~41% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588577887?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588577887","market":"us","top_or_hot":-1,"title":"BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal</title></head><body><p>** Shares of women's health firm Daré Bioscience <span>DARE.O</span> rise 6% to $1.91 premarket</p><p>** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm</p><p>** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co</p><p>** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations</p><p>** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation</p><p>** Including session's move, stock down ~41% YTD </p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 21:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal</title></head><body><p>** Shares of women's health firm Daré Bioscience <span>DARE.O</span> rise 6% to $1.91 premarket</p><p>** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm</p><p>** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co</p><p>** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations</p><p>** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation</p><p>** Including session's move, stock down ~41% YTD </p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL4N3X7128:1","article_id":"2588577887","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588577887","pubTimestamp":1764595712,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal** Shares of women's health firm Daré Bioscience DARE.O rise 6% to $1.91 premarket** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation** Including session's move, stock down ~41% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","DARE":"Dare Bioscience","BK4584":"避孕概念"},"translate_title":"拜耳退出Ovaprene合作协议，Buzz-DaréBioscience崛起","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DARE":0.9},"content_text":"BUZZ-Daré Bioscience rises as Bayer exits Ovaprene partnership deal** Shares of women's health firm Daré Bioscience DARE.O rise 6% to $1.91 premarket** Co says it will regain full rights to its experimental contraceptive ovaprene after Bayer HealthCare decided to end its partnership with the U.S. biotech firm** The move gives Daré control over ovaprene as it enters late-stage testing, offering more flexibility on commercialization - co** Daré CEO Sabrina Martucci Johnson says recent trial results showed ovaprene was safe and well tolerated, with pregnancy rates matching expectations** Co expects to finish enrolling patients in its ongoing late-stage trial next year; study funded by grants including Gates Foundation** Including session's move, stock down ~41% YTD  (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588577887","isCrawlerRequest":true}